NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT02992340 2021-01-14
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
ASLAN Pharmaceuticals
Phase 1/2 Terminated
NCT01679405 2019-09-06
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
Phase 1 Terminated
NCT00955721 2018-01-03
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
Phase 1/2 Terminated
NCT00868998 2016-05-23
GTX Regimen for Biliary Cancers
Columbia University
Phase 2 Terminated
NCT01949870 2016-05-13
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
Phase 1 Terminated
NCT01171755 2014-05-21
GetBil
Samsung Medical Center
Phase 2 Terminated
NCT01096745 2011-06-23
Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer
Gyeongsang National University Hospital
Phase 2 Terminated